Correlation of circulating insulin-like growth factor-1 and clinicopathological parameters in colorectal cancer

doi:10.3969/j.issn.1673-8640.2017.01.001

Abstract

Abstract:

Objective To investigate circulating insulin-like growth factor-1（IGF-1） in the progression of colorectal cancer （CRC）. Methods The levels of circulating IGF-1,carcinoembryonic antigen（CEA） and carbohydrate antigen 19-9 （CA19-9） were determined by chemiluminescence in 196 patients with CRC and 241 healthy controls. Results The level of circulating IGF-1 in CRC group [（143.86±55.07）ng/mL] was higher than that in healthy control group [（133.60±46.76）ng/mL]（P<0.05）. In healthy control group,the level of circulating IGF-1 in male group was higher than that in female group,which decreased with the increasing of age（P<0.05）. The risk of CRC was high relatively in subjects with high circulating IGF-1 [odds ratio（OR）=1.72,95% confidence interval（CI） 1.049-2.835,P<0.05]. The level of circulating IGF-1 was higher in CRC group with tumor≥5 cm,at advanced stages（stage Ⅲ and stages Ⅳ）,with low differentiation and with lymphoid node metastasis than those with tumor <5 cm,at early stages （stage Ⅰ and stage Ⅱ）,with middle and high differentiation and without lymphoid node metastasis （P<0.05）. The levels of CEA and CA19-9 were correlated to the pathological staging of tumor. The sensitivity of circulating IGF-1 combined determination with CEA and CA19-9 （58.16%）was higher than those of single items （23.98% for circulating IGF-1,32.22% for CEA and 15.31% for CA19-9）（P<0.05）. Conclusions Circulating IGF-1 is an independent risk factor for CRC and plays an important role in the progression of CRC,and it has clinical significance for the prognosis evaluation of CRC. Circulating IGF-1 combined determination with CEA and CA19-9 could improve the determination sensitivity for CRC.

Key words: Insulin-like growth factor-1, Carcinoembryonic antigen, Carbohydrate antigen 19-9, Colorectal cancer

CLC Number:

R446.62

XU Dandan, WANG Ruyao, LIU Rui, ZHAO Lijie, HU Liling, SUN Ao, WU Ping. Correlation of circulating insulin-like growth factor-1 and clinicopathological parameters in colorectal cancer[J]. Laboratory Medicine, 2017, 32(1): 1-4.

Figures/Tables 1

References 18

1	FERLAY J, SHIN H R, BRAY F, et al.Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008[J]. Int J Cancer,2010,127(12):2893-2917.
2	陈万青,郑荣寿,曾红梅,等. 2011年中国恶性肿瘤发病和死亡分析[J]. 中国肿瘤,2015,24(1):1-10.
3	RINALDI S,CLEVELAND R,NORAT T,et al.Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies[J]. Int J Cancer,2010,126(7):1702-1715.
4	CHEN W,WANG S,TIAN T,et al.Phenotypes and genotypes of insulin-like growth factor 1,IGF-binding protein-3 and cancer risk: evidence from 96 studies[J]. Eur J Hum Genet,2009,17(12):1668-1675.
5	KILIC L,YILDIZ I,SEN F K,et al.D-dimer and international normalized ratio (INR) are correlated with tumor markers and disease stage in colorectal cancer patients[J]. Cancer Biomark,2015,15(4):405-411.
6	秦俭,滕家安,梁远,等. 2型糖尿病合并结直肠癌患者血清IGF-I、IGFBP-3的变化及临床意义[J].广西医科大学学报,2009,26(6):886-888.
7	WU Y, YAKAR S, ZHAO L, et al.Circulating insulin-like growth factor-1 levels regulate colon cancer growth and metastasis[J]. Cancer Res,2002,62(4):1030-1035.
8	PROBST-HENSCH N M,YUAN J M, STANCZYK F Z, et al. IGF-1, IGF-2 and IGFBP-3 in prediagnostic serum: association with colorectal cancer in a cohort of Chinese men in Shanghai[J]. Br J Cancer,2001,85(11):1695-1699.
9	PANDINI G,FRASCA F, MINEO R, et al.Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved[J]. J Biol Chem,2002,277(42):39684-39695.
10	HANSON A M,KITTILSON J D,MARTIN L E,et al.Environmental estrogens inhibit growth of rainbow trout (oncorhynchus mykiss) by modulating the growth hormone-insulin-like growth factor system[J]. Gen Comp Endocrinol,2014,196:130-138.
11	万德森. 我国结直肠癌的流行趋势及对策[J]. 中华肿瘤杂志, 2011,33(7):481-483.
12	TRIPKOVIC I, TRIPKOVIC A, STRNAD M, et al.Role of insulin-like growth factor-1 in colon cancerogenesis: a case-control study[J]. Arch Med Res,2007,38(5):519-525.
13	POLLACK M N.Insulin, insulin-like growth factors,insulin resistance,and neoplasia[J]. Am J Clin Nutr,2007,86(3):s820-s822.
14	张军, 吴毅平. 结肠癌患者血清IGF-1水平及癌组织VEGF表达的临床意义[J]. 华中科技大学学报(医学版),2006,35(2):221-223.
15	CAO H, JIN C, HUANG D, et al.Changes in serum IGF-1 level and tumor VEGF expression in mice with colorectal cancer under hyperglycemic conditions[J]. Mol Med Rep,2013,7(4):1361-1365.
16	张红巧,吴敏,王丽娟,等. 检测血清癌胚抗原和癌相关糖抗原19-9对结直肠癌的临床价值[J]. 中国实用医刊,2009,36(16):43-44.
17	CHEN C C,YANG S H,LIN J K,et al.Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer?[J]. Surg Res,2005,124(2):169-174.
18	赵先文, 江波, 韩存芝, 等.大肠癌患者血清肿瘤标志物含量测定与临床研究[J]. 中华肿瘤杂志,2005,27(5):286-288.

组别	例数	IGF-1（ng/mL）	CEA（ng/mL）	CA19-9（U/mL）
肿瘤部位
直肠癌组	124	142.94±55.00	4.04（2.38,7.02）	9.85（5.73,20.55）
结肠癌组	72	145.45±55.53	3.23（2.16,8.78）	9.60（4.40,28.70）
肿瘤长径
<5 cm组	126	137.94±49.75	3.49（2.20,6.15）	9.80（5.50,23.18）
≥5 cm组	70	154.51±62.50^*	4.45（3.31,11.18）	9.90（5.50,19.00）
淋巴结转移
无转移组	113	134.84±50.80	4.04（2.40,7.37）	11.30（6.10,21.90）
有转移组	83	156.14±58.49^#	3.25（2.00,7.35）	8.30（4.25,22.98）
分期^△
Ⅰ期组	35	124.32±48.77	2.55（1.95,3.49）	6.80（3.85,16.23）
Ⅱ期组	77	140.78±51.66	4.08（2.20,7.84）	11.30（5.80,21.25）
Ⅲ+Ⅳ期组	84	154.44±58.68	4.44（2.94,11.32）	11.10（5.75,27.85）
分化程度^▲
高分化组	30	118.98±37.78	5.02（1.86,13.50）	8.30（4.30,22.60）
中分化组	156	141.40±55.68	3.66（2.25,7.03）	9.85（5.50,21.18）
低分化组	10	164.93±51.71	4.68（2.76,14.24）	18.15（9.00,37.90）

组别	例数	IGF-1（ng/mL）	CEA（ng/mL）	CA19-9（U/mL）
肿瘤部位
直肠癌组	124	142.94±55.00	4.04（2.38,7.02）	9.85（5.73,20.55）
结肠癌组	72	145.45±55.53	3.23（2.16,8.78）	9.60（4.40,28.70）
肿瘤长径
<5 cm组	126	137.94±49.75	3.49（2.20,6.15）	9.80（5.50,23.18）
≥5 cm组	70	154.51±62.50^*	4.45（3.31,11.18）	9.90（5.50,19.00）
淋巴结转移
无转移组	113	134.84±50.80	4.04（2.40,7.37）	11.30（6.10,21.90）
有转移组	83	156.14±58.49^#	3.25（2.00,7.35）	8.30（4.25,22.98）
分期^△
Ⅰ期组	35	124.32±48.77	2.55（1.95,3.49）	6.80（3.85,16.23）
Ⅱ期组	77	140.78±51.66	4.08（2.20,7.84）	11.30（5.80,21.25）
Ⅲ+Ⅳ期组	84	154.44±58.68	4.44（2.94,11.32）	11.10（5.75,27.85）
分化程度^▲
高分化组	30	118.98±37.78	5.02（1.86,13.50）	8.30（4.30,22.60）
中分化组	156	141.40±55.68	3.66（2.25,7.03）	9.85（5.50,21.18）
低分化组	10	164.93±51.71	4.68（2.76,14.24）	18.15（9.00,37.90）

[1]	LI Liangshan, ZHAO Hu, WANG Shiwen. Screening potential prognostic biomarkers of colorectal cancer based on weighted gene co-expression network analysis [J]. Laboratory Medicine, 2023, 38(9): 825-832.
[2]	ZHU Rixiang, YIN Jie. Relationship between soluble growth stimulating gene 2 protein and clinicopathological features and prognosis in patients with colorectal cancer [J]. Laboratory Medicine, 2023, 38(7): 629-633.
[3]	JIANG Mengying, LIU Yiwen, HE Yiqing, XU Jing, YANG Cuixia, GAO Feng, DU Yan. Clinical role of serum S1P in the early diagnosis of colorectal cancer [J]. Laboratory Medicine, 2023, 38(4): 307-312.
[4]	ZHANG Guoliang, LIU Yiwen, HE Yiqing, XU Jing, YANG Cuixia, GAO Feng, LIU Hua. Roles of serum HYAL1 and HA in the auxiliary diagnosis and therapeutic monitoring of colorectal cancer [J]. Laboratory Medicine, 2023, 38(4): 313-319.
[5]	YANG Jielin, WANG Xiaoyuan, LI Haixia. Expression and interaction of TRX and TXNIP in colorectal cancer [J]. Laboratory Medicine, 2023, 38(4): 330-336.
[6]	ZHOU Furong, LI Yanzhu, LIU Yonggan. Application of lncRNA SNP in colorectal cancer susceptibility prediction and prognosis assessment [J]. Laboratory Medicine, 2023, 38(12): 1206-1210.
[7]	ZHANG Cheng, FEI Chunxia, FU Lin, GAO Chenfei, NI Dongying. Correlation analysis of FGF-2,Lp-PLA2 and IGF-1 levels and disease severity in patients with diabetic foot [J]. Laboratory Medicine, 2022, 37(9): 826-830.
[8]	ZHU Yunjie, MA Zhengyao, SHEN Minna, ZHOU Yan, HUANG Fei, CHEN Xinning, ZHANG Chunyan, WANG Beili, GUO Wei. Establishment and clinical application evaluation of plasma cfDNA determination in colorectal cancer patients [J]. Laboratory Medicine, 2022, 37(6): 561-567.
[9]	GONG Zhiyun, JIANG Minglei, SHI Weizhong, LU Renquan, GUO Lin. Application value of fecal SDC2 gene methylation determination in the auxiliary diagnosis of colorectal cancer [J]. Laboratory Medicine, 2022, 37(4): 325-329.
[10]	LIU Kai, ZHANG Peiru, XIE Suhong, GUO Lin, LU Renquan. Clinical value of the SorCS1 gene promoter methylation determination in patients with colorectal cancer [J]. Laboratory Medicine, 2022, 37(4): 330-335.
[11]	CHEN Si, LIU Hua, LIU Yiwen, HE Yiqing, ZHANG Guoliang, YANG Cuixia, DU Yan, GAO Feng. Clinical significance of combined determination of serum HER-2 and CD44 in colorectal cancer [J]. Laboratory Medicine, 2022, 37(4): 336-341.
[12]	XIONG Zhongbo, WANG Lei, YIN Beiqi, DAI Yue, WEI Xiaoqing, LU Pei. Clinical roles of SAA and CRP in pathological staging and metastasis of gastrointestinal cancer [J]. Laboratory Medicine, 2022, 37(1): 51-55.
[13]	YANG Chaomei, FENG Jie, LANG Lei, YAN Guangtao. Clinical application value of CTC combined determination with CEA and CA125 in colorectal cancer [J]. Laboratory Medicine, 2021, 36(9): 901-905.
[14]	HU Tao, LU Renquan, GUO Lin. Auxiliary diagnostic and clinical prognostic evaluation value of thymidine kinase 1 determination in hepatocellular cancer [J]. Laboratory Medicine, 2021, 36(9): 914-919.
[15]	YANG Yong. Roles of SCC-Ag,CA19-9 and VEGF for chemotherapy efficacy in advanced esophageal squamous cell carcinoma [J]. Laboratory Medicine, 2021, 36(1): 20-24.